Skip to search formSkip to main contentSkip to account menu

TAK 385

Known as: GnRH Antagonist TAK-385, TAK-385, TAK385 
An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Relugolix

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A peek into the drug development scenario of endometriosis - A systematic review.
Review
2017
Review
2017
TO “ QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS : A SYSTEMATIC REVIEW AND META-ANALYSIS ” MORE ATTENTION TO SUBTLE SYMPTOMS , ENVIRONMENTAL CAUSES PREVENTION AND BETTER INFERTILITY TREATMENT CAN…
In their systematic review and meta-analysis articles, Chaman-ara at al (1) confirm that endometriosis negatively affects all… 
2015
2015
2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)